News

John Riggi, AHA’s senior advisory for cyber security and risk, speaks with Edward You, supervisory special agent in the FBI’s Weapons of Mass Destruction Directorate, about the biggest national threats to the bioeconomy, medical research and innovation. Listen here. 

Cordis Corporation recently re

In a study of more than 4,900 health care workers across 33 sites in 25 U.S. states, the Pfizer and Moderna COVID-19 vaccines were 89% and 96% effective, respectively, at preventing symptomatic COVID-19 infections in fully vaccinated workers, according to final results reported yesterday in the New England Journal of Medicine.

The AHA today released the latest edition of the COVID-19 Snapshot, underscoring the persisting challenges facing hospitals and health systems during

The Food and Drug Administration today required certain COVID-19 test developers to evaluate how SARS-CoV-2 mutations impact their test’s performance and update the labeling for the product accordingly.

The Food and Drug Administration late last night amended Pfizer’s emergency use authorization for its COVID-19 vaccine to allow for an additional, booster dose for certain individuals. FDA will authorize a booster shot to be administered six months following a completed two-dose regiment for the following:

The AHA’s American Organization for Nursing Leadership affiliate has elected as its 2022 president-elect Deborah Zimmermann.

In AHA’s newest #MyWhy video, nine hospital employees from UAB Medicine in Alabama candidly discuss their COVID-19 vaccine experience, starting with initial hesitancies and navigating misinformation surrounding the vaccine’s development and rumored side effects.

The Joint Commission today named as its next president and CEO effective March 1 Jonathan Perlin, M.D.

The Centers for Medicare & Medicaid Services yesterday began publicly sharing COVID-19 vaccination rates for nursing home staff and residents on its Care Compare website. 

The House last night voted 220-211 to pass a continuing resolution that would generally extend current federal funding levels for health care and all other programs through Dec. 3.

The House Energy and Commerce Subcommittee on Oversight and Investigations today held a hearing examining the impact of COVID-19 on children.

The Food and Drug Administration approved the first biosimilar to treat neovascular age-related macular degeneration, a leading cause of vision loss and blindness for seniors.

The Centers for Medicare & Medicaid Services granted certain Medicare quality reporting exceptions to acute-care hospitals, ambulatory surgical centers, prospective payment system-exempt cancer hospitals, inpatient psychiatric facilities, inpatient rehabilitation facilities, long-term care hospitals and skilled nursing facilities in counties affected by Hurricane Ida.

Clinicians caring for individuals recently evacuated from Afghanistan should alert their state or local health department of suspected measles cases, and recommend the measles, mumps and rubella (MMR) vaccine for unvaccinated patients, the Centers for Disease Control and Prevention advised, noting that 16 confirmed cases of measles and four cases of mumps have been reported among evacuees to date.

In a study reported in JAMA Network Open, rural hospital mergers were associated with lower mortality for patients admitted to the hospital for heart attack, heart failure, stroke and pneumonia.

Johnson & Johnson said its phase 3 trial data confirms its vaccine’s durability and provided evidence of a second, booster shot’s effectiveness against COVID-19.

The House is expected to consider a continuing resolution that would generally extend current federal funding levels for health care and all other programs through Dec. 3.

U.S. hospitals will lose an estimated $54 billion in net income this year, even after federal relief funds, as higher labor and other expenses and sicker patients impact their financial health during the ongoing COVID-19 pandemic, according to a report by Kaufman, Hall & Associates released by the AHA.

The Brigham Comprehensive Opioid Response and Education program and McLean Hospital of Belmont, Mass., on Sept. 21 at 12 p.m. ET will host a town hall virtual event, during which experts and those with experience with substance misuse and treatment will discuss COVID-19’s impact on these experiences, as well as solutions.